NOT-DA-17-059: Notice of Intent to Publish a Funding Opportunity Announcement for International Research Collaboration on Drug Abuse and Addiction Research (R01, Clinical Trial Optional)

Notice of Intent to Publish a Funding Opportunity Announcement for International Research Collaboration on Drug Abuse and Addiction Research (R01, Clinical Trial Optional)

Notice Number: NOT-DA-17-059

Key Dates
Release Date: November 29, 2017

Estimated Publication Date of Announcement: January 2018
First Estimated Application Due Date: February 5, 2018
Earliest Estimated Award Date: July 2018
Earliest Estimated Start Date: July 2018

Related Announcements
PA-15-142
PA-18-568

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse (NIDA) intends to reissue the International Research Collaboration on Drug Abuse and Addiction Research (R01, Clinical Trial Optional) to solicit applications that encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects.

The FOA is expected to be published January 2018 with an expected application due date in February 2018.

This FOA will utilize the R01activity code. Details of the planned FOA are provided below.

Research Initiative Details

This Notice encourages investigators with expertise and interest in any area of NIDA-supported research and access to resources outside the United States to begin to consider applying for this new FOA.

Collaborative investigations combining expertise in linkages between HIV/AIDS and drug abuse; prevention, initiation and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with comorbid disorders); the neuroscience of marijuana and cannabinoids; and the effects of changes in laws and policies on marijuana and their impact will be particularly encouraged.
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.

Inquiries

Please direct all inquiries to:

Steven Gust, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6480
Email: ipdirector@nida.nih.gov